However, an interim analysis from the Action in Diabetes and Vascular Disease trial,11,27,28 with 11,140 patients with DM at high risk for CVDs, found no evidence that intensive treatment (target levels of e6.5%) increased the risk of cardiovascular mortality compared with standard glucose-lowering treatment